GlucoTrack Research and Development Expenses 2011-2024 | GCTK

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

GlucoTrack research and development expenses from 2011 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.

GlucoTrack Research and Development Expenses 2011-2024 | GCTK

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

GlucoTrack research and development expenses from 2011 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.

Related Stocks
Company Name	Market Cap
Abbott Laboratories (ABT)	$202.6B
Stryker (SYK)	$144.4B
Boston Scientific (BSX)	$130.4B
Medtronic (MDT)	$113.2B
EssilorLuxottica (ESLOY)	$112.1B
Lonza Group Ag (LZAGY)	$45.3B
Haleon (HLN)	$43B
GE HealthCare Technologies (GEHC)	$39B
ResMed (RMD)	$36.5B
Terumo (TRUMY)	$30.6B
Koninklijke Philips (PHG)	$24.9B
Zimmer Biomet Holdings (ZBH)	$21.8B
Insulet (PODD)	$19.3B
Baxter (BAX)	$17.5B
Smith & Nephew SNATS (SNN)	$10.8B
Bio-Rad Laboratories (BIO)	$10.2B
BellRing Brands (BRBR)	$9.2B
Demant (WILYY)	$8.4B
Lantheus Holdings (LNTH)	$5.8B
TG Therapeutics (TGTX)	$4.8B
Haemonetics (HAE)	$4.6B
ICU Medical (ICUI)	$4.4B
Prestige Consumer Healthcare (PBH)	$4B
Perrigo (PRGO)	$3.6B
Envista Holdings (NVST)	$3.6B
Neogen (NEOG)	$3.6B
Agios Pharmaceuticals (AGIO)	$3.4B
GN Store Nord (GNNDY)	$3.1B
Shandong Weigao Medical Polymer (SHWGF)	$3B
QuidelOrtho (QDEL)	$2.9B